Japan & Eli Lilly and Company

Japan: Japan's Nikkei 225 index saw substantial gains, supported by tech-related shares and positive economic indicators like manufacturing PMI and export data, reflecting a healthy market performance.

Eli Lilly and Company: Eli Lilly and Company>>> advanced after positive trial results for its next-generation obesity drug, retatrutide, which showed benefits beyond weight loss.

Japan: Japan is a key market for Nxera, with increasing revenues from PIVLAZ and QUVIVIQ. The company's commercial business in Japan continues to grow.

Eli Lilly and Company: Eli Lilly completed its acquisition of KC Pharmaceuticals, strengthening its sleep disorder portfolio. Nxera retains rights to future milestone and royalty payments from the orexin programs, benefiting Lilly's pipeline.

Japan: Nikkei fell sharply; yen at 40-year low.

Eli Lilly and Company: Eli Lilly's stock jumped after a committee of the European Medicines Agency recommended one of its medicines for approval, boosting its market performance.

Japan: Japan is Eisai's home country and an existing market for Leqembi; the India launch has minimal direct impact.

Eli Lilly and Company: Eli Lilly faces increased competition in India's Alzheimer's market as Eisai launches Leqembi, potentially impacting its Lormalzi uptake.